Trial Profile
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 17 Jul 2020 Status changed from recruiting to completed.
- 08 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 08 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.